Method of treating cancer cells
The present invention discloses a method of treating cancer cells. The method comprises administrating a composition comprises a rhodamine or rhodamine derivative conjugated to a peptide comprises an amino acid sequence of SEQ ID NO: 1 to a subject in need, and activate the composition with light.
1. A method of treating head and neck squamous cell carcinoma, comprising:
administering a composition comprising a rhodamine or rhodamine derivative conjugated to a peptide comprising an amino acid sequence of SEQ ID NO: 1 to a subject suffering from head and neck squamous cell carcinoma, and
activating the composition with light, wherein the rhodamine or the rhodamine derivative is selected from the group consisting of: Carboxytetramethylrhodamine (TAMRA), Tetramethylrhodamine (TMR) and 5/6-tetramethyl-rhodamine isothiocyanate (TRITC).
2. The method of claim 1 , wherein the composition is administered into a mass of cancer cells of the head and neck squamous cell carcinoma.
3. The method of claim 1 , wherein the composition induces apoptosis of the cancer cells of the head and neck squamous cell carcinoma.
4. The method of claim 3 , wherein the apoptosis is independent of caspase activation.
5. The method of claim 1 , wherein the composition induces mitochondria fragmentation of the cancer cells of the head and neck squamous cell carcinoma.
6. The method of claim 1 , wherein the composition induces reactive oxygen species (ROS) generation of the cancer cells of the head and neck squamous cell carcinoma.
7. The method of claim 1 , wherein the composition induces DNA damage of the cancer cells of the head and neck squamous cell carcinoma.
8. The method of claim 1 , wherein the light is with a wavelength of 380 nm to 750 nm.
9. The method of claim 8 , wherein the light is with a wavelength of 400 nm to 620 nm.
10. The method of claim 9 , wherein the light is with a wavelength of 470 nm to 580 nm.